Physician profile
Christian G Nageotte
NPI 1780785204
$47,175.50
in general payments reported to CMS, 2019-2025
7 companies · $9,760 in 2025
The $9,760 reported for 2025 was more than what 86% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,557 · 2020: $7,219 · 2021: $7,709 · 2022: $4,474 · 2023: $9,500 · 2024: $5,956 · 2025: $9,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $2,370 · Travel and Lodging: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,296.13 |
| Food and Beverage | $2,369.84 |
| Travel and Lodging | $1,550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $29,310.60 | 2019-2025 | Dupixent |
| Genzyme Corporation | $16,062.92 | 2020-2024 | |
| Astrazeneca Pharmaceuticals Lp | $1,423.58 | 2021-2025 | Fasenra, Tezspire |
| Csl Behring | $124.74 | 2025 | Andembry |
| Amgen INC. | $122.14 | 2023 | Tezspire |
| Glaxosmithkline, LLC. | $98.12 | 2022 | |
| Genentech USA, INC. | $33.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Nageotte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.